Caminati Marco, Guarnieri Gabriella, Batani Veronica, Scarpieri Elena, Finocchiaro Anita, Chieco-Bianchi Fulvia, Senna Gianenrico, Vianello Andrea
Department of Medicine, University of Verona, 37124 Verona, Italy.
Respiratory Pathophysiology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.
Vaccines (Basel). 2021 Aug 4;9(8):853. doi: 10.3390/vaccines9080853.
COVID-19 vaccination has been recommended for severe asthmatics. We aimed to evaluate the safety, tolerability, and impact on disease control and patient's quality of life of the mRNA SARS-CoV-2/COVID-19 vaccine in severe asthma patients regarding biologic treatment.
Severe asthmatic patients regularly managed by two big allergy and respiratory referral centers were offered to undergo Pfizer COVID 19 vaccination at the hospital site. Patients filled in an adverse events questionnaire after the first and second dose, as well as the Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire (AQLQ).
Overall, 253 patients were vaccinated; only 16 patients refused. No serious events were detected. Less than 20% of patients reported side effects, most of which were classified as very common side effects. No differences were reported according to the ongoing biologic drug. A significant improvement in both ACT and AQLQ was observed between the first and the second dose administration.
Our data confirm the optimal safety and tolerability profile of mRNA SARS- CoV-2/COVID-19 in severe asthma patients on biologic treatment, as well as their positive attitude towards COVID-19 vaccination. The negligible proportion of patients reporting side effects and the absence of asthma exacerbations are relevant to support the COVID-19 vaccination campaign in severe asthma patients worldwide.
已建议重度哮喘患者接种新冠疫苗。我们旨在评估mRNA SARS-CoV-2/新冠疫苗在接受生物治疗的重度哮喘患者中的安全性、耐受性，以及对疾病控制和患者生活质量的影响。
由两个大型过敏和呼吸病转诊中心定期管理的重度哮喘患者被邀请在医院现场接种辉瑞新冠疫苗。患者在接种第一剂和第二剂后填写不良事件问卷，以及哮喘控制测试（ACT）和哮喘生活质量问卷（AQLQ）。
总体而言，253名患者接种了疫苗；只有16名患者拒绝。未检测到严重事件。不到20%的患者报告有副作用，其中大多数被归类为非常常见的副作用。根据正在使用的生物药物，未报告差异。在接种第一剂和第二剂之间，ACT和AQLQ均有显著改善。
我们的数据证实了mRNA SARS-CoV-2/新冠疫苗在接受生物治疗的重度哮喘患者中的最佳安全性和耐受性，以及他们对新冠疫苗接种的积极态度。报告有副作用的患者比例可忽略不计，且无哮喘加重情况，这为全球重度哮喘患者的新冠疫苗接种运动提供了有力支持。
